Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
100g |
|
||
Other Sizes |
|
Purity: ≥98%
Dexamethasone Acetate (also known as NSC 39471) is the 21-acetoxy (ester) form of Dexamethasone, it is a potent synthetic glucocorticoid class of steroid drugs, and an interleukin receptor modulator with anti-inflammatory and immunosuppressive activities. Dexamethasone has anti-inflammatory and immunosuppressant effects. It is 25-fold more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect.
ln Vitro |
Important genes involved in the inflammatory response are activated and inhibited by nuclear factor-AT, nuclear factor-kB, and protein-1 [1]. With an EC50 of 2.2 nM, dexamethasone acetate efficiently suppresses the release of colony-stimulating factor (GM-CSF) from granulocyte-macrophage A549 cells. At concentrations 10-100 times greater than those that suppress GM-CSF production, dexamethasone acetate (EC50=36 nM) is shown to be linked to glucocorticoid receptor (GR) DNA binding and to the induction of β2 receptor transcription. The inhibition of GM-CSF release is linked to the inhibition of 3×κB (NF-κB, IκBα, and I-κBβ) by dexamethasone acetate (IC50=0.5 nM).
|
||
---|---|---|---|
ln Vivo |
Dexamethasone acetate 10 mg/kg (ip) administered as a single dosage dramatically decreased both the spontaneous production of oxygen free radicals and the recruitment of granulocytes [3]. animals given Dexamethasone acetate had lower food intake and weight reductions compared to animals given control. Despite eating the same amount of food, the treated rats weighed less than the animals fed in pairs. The liver-to-body weight ratio (+65%) and liver mass (+42%) significantly increased after receiving injections of dexamethasone acetate for five days. After five days of treatment, the wet weight of the gastrocnemius muscle dropped by 20%, but it did not change in relation to body weight (g/100 g body weight), suggesting that weight reduction and muscle weight loss were synchronized [4].
|
||
Animal Protocol |
|
||
References |
[1]. LaLone CA, et al. Effects of a glucocorticoid receptor agonist, Dexamethasone, on fathead minnow reproduction, growth, and development. Environ Toxicol Chem. 2012 Mar;31(3):611-22.
[2]. Adcock IM, et al. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol. 1999 Jun;127(4):1003-11 [3]. Rocksén D, et al. Differential anti-inflammatory and anti-oxidative effects of Dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation. Clin Exp Immunol. 2000 Nov;122(2):249-56 [4]. Roussel D, et al. Dexamethasone treatment specifically increases the basal proton conductance of rat liver mitochondria. FEBS Lett. 2003 Apr 24;541(1-3):75-9. [5]. Ballabh P, et al. Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids. Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89(1):F76-83. [6]. Heidi Ledford. et al. Coronavirus Breakthrough: Dexamethasone Is First Drug Shown to Save Lives. Nature. 2020 Jun 16. [7]. Yun Chen, et al. Glucocorticoids inhibit production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses. Int J Clin Exp Pathol 2018;11(7):3391-3397 |
Molecular Formula |
C24H31FO6
|
|
---|---|---|
Molecular Weight |
434.5
|
|
CAS # |
1177-87-3
|
|
Related CAS # |
Dexamethasone;50-02-2;Dexamethasone-d5;358731-91-6;Dexamethasone phosphate disodium;2392-39-4;Dexamethasone phosphate;312-93-6
|
|
SMILES |
F[C@]12[C@]3(C([H])=C([H])C(C([H])=C3C([H])([H])C([H])([H])[C@]1([H])[C@]1([H])C([H])([H])[C@@]([H])(C([H])([H])[H])[C@](C(C([H])([H])OC(C([H])([H])[H])=O)=O)([C@@]1(C([H])([H])[H])C([H])([H])[C@]2([H])O[H])O[H])=O)C([H])([H])[H]
|
|
InChi Key |
AKUJBENLRBOFTD-RPRRAYFGSA-N
|
|
InChi Code |
InChI=1S/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,13,17-19,28,30H,5-6,9,11-12H2,1-4H3/t13-,17+,18+,19+,21+,22+,23+,24+/m1/s1
|
|
Chemical Name |
2-((8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3015 mL | 11.5075 mL | 23.0150 mL | |
5 mM | 0.4603 mL | 2.3015 mL | 4.6030 mL | |
10 mM | 0.2301 mL | 1.1507 mL | 2.3015 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.